Navigation Links
Barr Reports First Quarter 2008 GAAP Earnings of $0.21 Per Share; Adjusted Earnings of $0.57 Per Share
Date:5/8/2008

- Strong European and Rest of the World Sales

- Proprietary Product Sales Increase, Portfolio Expanded - Company Provides Updated Adjusted Calendar 2008 EPS Guidance of $2.75 -

$3.05

MONTVALE, N.J., May 8 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today reported net earnings of $23 million, or $0.21 per share, on revenues of $608 million for the quarter ended March 31, 2008. The current quarter results compare with prior year net earnings of $12 million, or $0.11 per share, on revenues of $597 million. On a non-GAAP basis, adjusted earnings per share were $0.57 for the first quarter of 2008, as compared to $0.73 for the prior year period. A reconciliation of GAAP-based earnings per share to adjusted earnings per share is presented in the table at the end of this press release.

"While our results for the first quarter did not meet our expectations, we believe that these results will improve in the second half of the year and demonstrate the value of expanding our operations and markets outside the U.S.," said Bruce L. Downey, Barr's Chairman and CEO. "Strong sales growth in Europe and the Rest of the World (ROW) was driven by growth in the key markets of Germany, Russia and Poland. As expected, sales of our U.S. generic contraceptive portfolio decreased but are expected to grow from this level with the anticipated launch of generic Yasmin(R). During the quarter, we expanded our other generic U.S. product portfolio with the launch of generic versions of Fosamax(R) and Kytril(R) and continued to record strong year-over- year sales growth of our Fentanyl Citrate product. Proprietary sales increased year-over-year, driven by our Plan B(R) and SEASON
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
2. Dendreon Reports First Quarter 2008 Financial Results
3. Nutrition 21 Reports Fiscal Third Quarter 2008 Financial Results
4. Volcano Reports 24 Percent Increase in First Quarter Revenues; IVUS Disposable Revenues Increase 30 Percent
5. Oncothyreon Reports First Quarter 2008 Financial Results
6. iCAD Reports First Quarter 2008 Financial Results
7. AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results
8. American Oriental Bioengineering Reports First Quarter 2008 Financial Results
9. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
10. Onyx Pharmaceuticals Reports 2008 First Quarter Results
11. AtriCure Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 DTS Language Services, ... Online Web Portal for Life Science organizations who need document ... the subject matter of their documents in advance with a ... reduce time-to-delivery of translations, often a critical factor in clinical ...
(Date:1/15/2014)... TAIPEI , Jan. 15, 2014 TaiGen Biotechnology ... an exclusive agreement with R-Pharm, a leading Russian pharmaceutical ... in the Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic for ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
(Date:1/14/2014)... and BETHESDA, Md. , ... joining together with two institutes from the National Institutes ... tools for bringing safer, more effective treatments to patients ... National Center for Advancing Translational Sciences (NCATS) and the ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
...  Frank A. Critz, M.D., founder and medical director of Radiotherapy ... welcome this April when he returns to Fulton, Miss.  for ... will be April 14, 2012 at the Holiday Inn Express ... until 3 p.m., and lunch will be served. ...
... 20, 2012 The American College of Radiology (ACR) ... Donald P. Rosen, MD, chief executive officer of ACR ... research organization (CRO) and for-profit subsidiary of the ACR. ... of experience in radiology, including contract research and business ...
... Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm ... Virus (HIV) infections, announced today that it has ... pursuant to which the Company has agreed to ... stock at an aggregate purchase price of approximately ...
Cached Biology Technology:Radiotherapy Clinics of Georgia's Founder Returns Home to Celebrate Cancer Survivors and Receive Lifetime Achievement Award 2Imaging Contract-Research Pioneer, Donald P. Rosen, MD, Named CEO of ACR Image Metrix™ 2GeoVax Announces Private Placement of $2.2 Million 2GeoVax Announces Private Placement of $2.2 Million 3GeoVax Announces Private Placement of $2.2 Million 4
(Date:4/17/2014)... Calif. One day about eight years ago, ... California, Riverside, and her father were on a field trip ... upon an orchid they had never seen before. , Unable ... on orchids. The orchid turned out to be an ... Lophiaris silverarum . , "Lophiaris" is the genus name, ...
(Date:4/17/2014)... on a novel method to help kidney stone ... effective treatment possible., Kidney stones represent a major ... If left untreated, apart from being particularly painful, ... complications. In many patients treated successfully, stone recurrence ... pathological approach to diagnosis and treatment needs to ...
(Date:4/17/2014)... Gene expression is the process whereby the genetic ... products, such as proteins, which have numerous different ... as an important intermediary during gene expression, by ... molecular mechanisms involved in manufacturing proteins. , ... mRNA molecules present in an organism at a ...
Breaking Biology News(10 mins):Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3Rapid and accurate mRNA detection in plant tissues 2
... protein kinase is an essential regulator of cytoskeletal ... whether Rho kinase regulates microtubule remodeling or the ... remains unclear. By using the ROCK inhibitor, Y-27632, ... colleagues from First Affiliated Hospital of Jinan University ...
... know about MyPyramid the triangle depicting how many servings ... - but who knows about MyPlate - the circle showing ... 2011 by the United States Department of Agriculture (USDA) to ... a simple, colorful icon that prompts us to think about ...
... cell-based gene therapy holds promise for the treatment of devastating ... approach have been unclear. In a study online December 26th ... published by Cell Press, researchers evaluated a patient with a ... years after he had undergone a gene therapy procedure as ...
Cached Biology News:Who is using MyPlate? 2Gene therapy for human skin disease produces long-term benefits 2
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
SHP-2 Antibody...
200 μg per ml DNA in 10 SSPE, 2 Denhardt's...
... Reacts with an early ... infection 3 hours post-infection exhibiting ... reaches peak intensity between 6-24 ... extremely intense coarsely granular staining. ...
Biology Products: